Immune Checkpoint Blockade (ICB) has reshaped cancer care and can deliver durable remission in malignancies such as melanoma and non-small cell lung cancer.
Pelareorep combined with atezolizumab achieved a 29% ORR in heavily pretreated metastatic SCAC patients, significantly ...
A research team led by Professor Chen Peng from the College of Chemistry and Molecular Engineering at Peking University has ...
Scientists pinpoint two cancer genes that when deleted, improve the vulnerability of tumour cells to immunotherapy.
Vaxiion Therapeutics Announces Completion of Phase 1a Dose Escalation and Initiation of a Phase 1b Dose Expansion Study for Intralesional Administration of VAX014 in Combination with PD-1 Directed ...
A comprehensive analysis published in Reserch illuminates how cancer cells hijack immune checkpoints on natural killer (NK) cells to disable the body’s frontline defense system. The study details: ...
A landmark study headed by researchers at Yale School of Medicine and at Fred Hutchinson Cancer Center has revealed that autoantibodies (AAbs)—immune proteins traditionally associated with autoimmune ...
Phase 1b LANTERN clinical study is assessing tolododekin alfa, anchored IL-12 immunotherapy, in combination with anti PD-1/PD-L1 immune checkpoint blockade for treatment of non-small cell lung cancer ...
New research reports the creation of a degradation-based cancer vaccine that penetrates tumor cells and converts them into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results